FORESEE PHARMACEUTICALS CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. CAMCEVI 42 mg
2. CAMCEVI 21 mg
3. FP-025
4. FP-045
5. Aderamastat (FP-025) Phase 2 Study
2. CAMCEVI 21 mg
3. FP-025
4. FP-045
5. Aderamastat (FP-025) Phase 2 Study
The content above was translated by Ai
Founded Year
2013
Unified Business No.
54165507
Status
Active
Number of Employees
12
Total Paid-in
Capital
1,575,405,410 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
OTC listing(2018)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients' quality of life and provide cure through innovative research. We are committed to apply the highest ethical standards to our products, services and communications. Foresee's core competencyincludes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.
The content above was translated by Ai
